Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis[J]. N Engl J Med, 2007, 356(5): 459-468.
[2]
Pardanani AD, Levine RL, Lasho T, et al. MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients[J]. Blood, 2006, 108(10): 3472-3476.
[3]
Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia[J]. PLoS Med, 2006, 3(7): 270.
[4]
Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort[J]. Blood, 2008, 112(1): 141-149.
[5]
Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia[J]. Blood, 2008, 112(3): 844-847.
[6]
Guglielmelli P, Pancrazzi A, Berganaschi G, et al. Anemia characterizes patients with myelofibrosis harboring MPL mutation[J]. Br J Haematol, 2007, 137(3): 244-247.
Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review [J]. Am J Med, 1996, 100(5): 555-570.
[9]
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia[J]. N Engl J Med, 2002, 346(9): 645-652.
Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms [J]. Leukemia, 2008, 22(1): 14-22.
[13]
Mesa R, Verstovsek S, Cervantes F, et al. Primary myelofibrosis(PMF), post polycythemia vera myelofibrosis(post-PV MF), post essential thrombocythemia myelofibrosis(post-ETMF), blast phase PMF(PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment(IWGMRT)[J]. Leukemia Res, 2007, 31(6): 737-740.
[14]
Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: population-based study [J]. Haematologica, 2009, 94(6): 865-869.
[15]
Dingli D, Grand FH, Mahaffey V, et al. Der(6)t(1;6)(q21-23; p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia [J]. Br J Haematol, 2005, 130(2): 229-232.
Verstovsek S, Pardanani AD, Shah NP, et al. A phaseⅠstduy of XL019, a selective JAK2inhibitor, in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis[J]. Blood, 2007, 110.
[19]
Levine R, Heaney M. New advances in the pathogenesis and therapy of essential thrombocythemia[J]. Hematology, 2008, 207(1): 76-82.
[20]
Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders [J]. Semin Thromb Hemost, 2006, 32(3): 219-230.
[21]
Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results [J]. Leuk Res, 2006, 30(6): 739-744.
[22]
Tefferi A, Vardiman Jw. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J]. Leukemia, 2008, 22(1): 14-22.
[23]
James C, Ugo V, LE COUEDIC, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera [J]. Nature, 2005, 434(7037): 1144-1148.
[24]
Dalal I, Arpaia E, Dadi H, et al. Cloning and characterization of the human homolog of mouse Jak2[J]. Blood, 1998, 91(3): 844-851.
[25]
Baxter EJ, Seott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J]. Lancet, 2005, 365(9464): 1054-1061.
[26]
Zeuner A, Pedini F, Signore M, et al. Increased death receptor resistance and FLIP short expression in polycythemia vera erythroid precursor cells[J]. Blood, 2006, 107(9): 3459-3502.
Griesshammer M, Heinze B, Bangerter M, et al. Karyotype abnormalities and their clinical significance in blastcrisis of chronic myeloid leukemia[J]. J Mol Med, 1997, 75(11-12): 836-838.
[29]
Johansson B, Fioretos T, M itelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia[J]. Acta Haematol, 2002, 107(2): 76-94.
Cuenco GM, Ren R. Cooperation of BCR-ABL and AML1 /MDS1 /EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia [J]. Oncogene, 2001, 20(57): 8236-8248.
[32]
Dash AB, W illiams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR /ABL and NUP98 /HOXA9 [J]. Proc Natl Acad Sci USA, 2002, 99(11): 7622-7627.
[33]
Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase [J]. Proc Natl Acad Sci USA, 1991, 88(14): 6293-6297.
[34]
Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia [J]. Blood, 1995, 85(8): 2013-2016.
[35]
Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia [J]. Acta Haematol, 2002, 107(2): 76-94.
[36]
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J]. Lancet, 2005, 365(9464): 1054-1061.
[37]
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352(17): 1779-1790.
[38]
James C,Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J]. Nature, 2005, 434(7037): 1144-1148.
[39]
Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes [J]. Blood, 2005, 106(4): 1207-1209.
[40]
James C, Delhommeau F, Marzac C, et al. Detection of JAK2V617F as a first intention diagnostic test for erythrocytosis [J]. Leukemia, 2006, 20(2): 350-353.
[41]
Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis [J]. Haematologica, 2004, 89(10): 1194-1198.
[42]
Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis [J]. Mayo Clin Proc, 2005, 80(7): 947-958.
[43]
Campbell PJ, Linda MS, Georgina B, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study [J]. Lancet, 2005, 366(9501): 1945-1953.
[44]
Anthony JB, Heike LP. Chromosome abnormalities and molecular markers in myeloprolificative disorders [J]. Semin Hematol, 2005, 42(4): 196-205.
